Attached files

file filename
EX-99.1 - EX-99.1 - Vir Biotechnology, Inc.d945110dex991.htm
EX-10.59 - EX-10.59 - Vir Biotechnology, Inc.d945110dex1059.htm
EX-10.58 - EX-10.58 - Vir Biotechnology, Inc.d945110dex1058.htm
EX-10.57 - EX-10.57 - Vir Biotechnology, Inc.d945110dex1057.htm
EX-10.56 - EX-10.56 - Vir Biotechnology, Inc.d945110dex1056.htm
EX-10.55 - EX-10.55 - Vir Biotechnology, Inc.d945110dex1055.htm
EX-10.54 - EX-10.54 - Vir Biotechnology, Inc.d945110dex1054.htm
EX-10.53 - EX-10.53 - Vir Biotechnology, Inc.d945110dex1053.htm
EX-10.21 - EX-10.21 - Vir Biotechnology, Inc.d945110dex1021.htm
EX-5.1 - EX-5.1 - Vir Biotechnology, Inc.d945110dex51.htm
EX-1.1 - EX-1.1 - Vir Biotechnology, Inc.d945110dex11.htm
S-1 - S-1 - Vir Biotechnology, Inc.d945110ds1.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the reference to our firm under the caption “Experts” in the Registration Statement (Form S-1) and related Prospectus of Vir Biotechnology, Inc. for the registration of shares of its common stock and to the incorporation by reference therein of our report dated March 26, 2020, with respect to the consolidated financial statements of Vir Biotechnology, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2019, filed with the Securities and Exchange Commission.

 

/s/ Ernst & Young LLP
Redwood City, California
July 6, 2020